ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
企業コードNDRA
会社名ENDRA Life Sciences Inc
上場日Jun 28, 2017
最高経営責任者「CEO」Tokman (Alexander Y)
従業員数21
証券種類Ordinary Share
決算期末Jun 28
本社所在地3600 Green Ct Ste 350
都市ANN ARBOR
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号48105
電話番号17343350468
ウェブサイトhttps://www.endrainc.com/
企業コードNDRA
上場日Jun 28, 2017
最高経営責任者「CEO」Tokman (Alexander Y)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし